Hemogenyx Pharmaceuticals CEO Dr. Vladislav Sandler outlines 2023 progress with HEMO-CAR-T
Hemogenyx Pharmaceuticals CEO Dr. Vladislav Sandler discusses the company's significant progress with its HEMO-CAR-T product candidate in 2023, including the submission of an IND application to the FDA and a successful fundraising round.
The progress made by Hemogenyx Pharmaceuticals with its HEMO-CAR-T product candidate in 2023 is important as it signifies advancements in the treatment of relapsed refractory acute myeloid leukemia. This news impacts individuals interested in innovative cancer treatments and investors in the biopharmaceutical industry.